MedTrace Logo

Citicoline in Non-Arteritic Ischemic Optic Neuropathy

NCT03758118 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2023-11-24

Study results available
· View outcomes & findings →

Summary

The investigators tested the hypothesis whether the treatment with Citicoline in oral solution (OS-Citicoline) would increase or stabilize visual acuity, retinal ganglion cells (RGCs) function and neural conduction along the visual pathways (neuroenhancement), and/or induce preservation of RGCs fibers' loss (neuroprotection) in an human model of neurodegeneration: non-arteritic ischemic optic neuropathy (NAION).

Conditions

  • Non-arteritic Ischemic Optic Neuropathy

Interventions

DIETARY_SUPPLEMENT

Citicoline

Citicoline administered in oral solution

Sponsors & Collaborators

  • Fondazione G.B. Bietti, IRCCS

    lead OTHER

Principal Investigators

  • Vincenzo MF Parisi, MD · Fondazione Bietti- IRCCS

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-20
Primary Completion
2017-07-25
Completion
2018-04-25

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03758118 on ClinicalTrials.gov